Please login to the form below
simeprevir
This page shows the latest simeprevir news and features for those working in and with pharma, biotech and healthcare.
Remicade safe from biosimilar competition this year, says J&J
On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in
Latest news
-
2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky
to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
-
J&J's share buyback 'doesn't prevent acquisitions'
disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products.
-
J&J starts to feel biosimilar competition bite
its toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
-
J&J signs $1bn deal with Achillion for hepatitis C therapies
J&J already has one new-generation oral HCV therapy on the market, its NS3/4A protease inhibitor Olysio (simeprevir), but could do with additional drugs in its portfolio in order
-
Harvoni sales rocket in first quarter
simeprevir), while Merck &Co also has a new treatment in the works.
More from news
Approximately 9 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Taking a strategic approach
Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Medivir names new CEO
simeprevir). “ Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said. “
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Warehousing of HCV patients reaches new high
Gilead’ s interferon-free product sofosbuvir and Johnson &Johnson’ s simeprevir appear to lead the field – receiving the highest levels of spontaneous and prompted awareness. ... However, Abbvie’ s products ABT 267, ABT 333 and ABT 450 remain
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and bebefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Programme Executive
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Account Manager – Med Comms – London
-
Salary TBC
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and benefits
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
Subscribe to our email news alerts
PMHub
Cello Health Insight
Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
